Literature DB >> 25414124

Usefulness of the platelet-to-lymphocyte ratio in predicting bare-metal stent restenosis.

Samet Yılmaz1, Fatıh Sen, Sefa Ünal, Cağri Yayla, Özcan Özeke, Dursun Aras, Serkan Topaloglu, Sınan Aydogdu.   

Abstract

OBJECTIVES: Platelet-to-lymphocyte ratio (PLR) provides a simple method for assessment of inflammatory status. The aim of the present study was to investigate the predictive value of preprocedural PLR on development of in-stent restenosis in patients undergoing bare-metal stent (BMS) implantation.
DESIGN: Six hundred and seventy-five consecutive patients (mean age: 60.6 ± 8.3, 66% men) who had undergone successful BMS implantation and additional coronary angiography for stable or unstable angina pectoris were analyzed. Mean period between 2 coronary angiographies was 14.3 ± 3.4 months.
RESULTS: Patients were divided into tertiles based on preprocedural PLR. Restenosis occurred in 58 patients (26%) in the lowest tertile, in 82 (36%) in the middle tertile, and in 115 (51%) in the highest tertile (p < 0.001). Serum C-reactive protein levels were also significantly higher in patients in tertile 3 than in those in tertiles 1 and 2 (p < 0.001). Smoking, diabetes mellitus, high-density lipoprotein, stent length, preprocedural PLR, and C-reactive protein levels emerged as independent predictors of in-stent restenosis. In receiver-operating characteristics curve analysis, PLR >122 had 81% sensitivity and 72% specificity in predicting in-stent restenosis.
CONCLUSIONS: High preprocedural PLR is a powerful and independent predictor of BMS restenosis in patients with stable and unstable angina pectoris.

Entities:  

Keywords:  coronary artery disease; inflammation; stent restenosis

Mesh:

Substances:

Year:  2014        PMID: 25414124     DOI: 10.3109/14017431.2014.989537

Source DB:  PubMed          Journal:  Scand Cardiovasc J        ISSN: 1401-7431            Impact factor:   1.589


  7 in total

1.  Increased Platelet-to-Lymphocyte Ratios and Low Relative Lymphocyte Counts Predict Appropriate Shocks in Heart Failure Patients with ICDs.

Authors:  Kevser Gülcihan Balci; Mustafa Mücahit Balci; Ugur Arslan; Burak Açar; Orhan Maden; Hatice Selcuk; Timur Selcuk
Journal:  Acta Cardiol Sin       Date:  2016-09       Impact factor: 2.672

2.  Predictive Value of Lymphocyte-to-monocyte Ratio in Patients with Contrast-induced Nephropathy After Percutaneous Coronary Intervention for Acute Coronary Syndrome.

Authors:  Irem Karauzum; Kurtulus Karauzum; Burak Acar; Kaan Hanci; Halil Ibrahim Ulas Bildirici; Teoman Kilic; Ertan Ural
Journal:  J Transl Int Med       Date:  2021-07-09

3.  Relationship between platelet-to-lymphocyte ratio and the presence and severity of coronary artery ectasia.

Authors:  Harun Kundi; Murat Gök; Mustafa Çetin; Emrullah Kızıltunç; Hülya Çiçekcioğlu; Zehra Güven Çetin; Orhan Karayiğit; Ender Örnek
Journal:  Anatol J Cardiol       Date:  2016-04-21       Impact factor: 1.596

Review 4.  Vascular Wall Reactions to Coronary Stents-Clinical Implications for Stent Failure.

Authors:  Tommaso Gori
Journal:  Life (Basel)       Date:  2021-01-17

5.  Albumin to globulin ratio was associated with in-stent restenosis and revascularization events after percutaneous coronary intervention.

Authors:  Rui Zhang; Zaixiao Tao; Jing Gong; Zhenjun Ji; Mingming Yang; Genshan Ma; Yongjun Li
Journal:  Clin Transl Sci       Date:  2022-02-27       Impact factor: 4.438

6.  The relation of platelet-lymphocyte ratio and coronary collateral circulation in patients with non-ST segment elevation myocardial infarction.

Authors:  Serkan Akdag; Aytac Akyol; Muntecep Asker; Fatih Ozturk; Hasan Ali Gumrukcuoglu
Journal:  Postepy Kardiol Interwencyjnej       Date:  2016-08-19       Impact factor: 1.426

7.  Association of epicardial adipose tissue thickness and inflammation parameters with CHA2DS2-VASASc score in patients with nonvalvular atrial fibrillation.

Authors:  Serkan Akdag; Hakki Simsek; Musa Sahin; Aytac Akyol; Ramazan Duz; Naci Babat
Journal:  Ther Clin Risk Manag       Date:  2015-11-06       Impact factor: 2.423

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.